Ibuprofen and Pseudoephedrine Comparative Pharmacokinetic Study

Healthy Clinical Trial

Official title:

An Open-label, Randomised, Three-way Cross-over, Single Dose, Single Centre, Comparative Pharmacokinetic Study Between Ibuprofen and Pseudoephedrine Liquid Capsules (2x 200 mg Ibuprofen & 30 mg Pseudoephedrine) (Test), Ibuprofen and Pseudoephedrine Tablets (2x 200 mg Ibuprofen & 30 mg Pseudoephedrine) (Comparator 1), and Ibuprofen Liquid Capsules (2x 200 mg Solubilised Ibuprofen) (Comparator 2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03184766
• Other study ID #: NL1309
• Status: Completed
• Phase: Phase 1
• First received: May 17, 2017
• Last updated: June 8, 2017
• Start date: August 10, 2016
• Est. completion date: January 30, 2017

Study information

• Verified date: April 2017
• Source: Reckitt Benckiser Healthcare (UK) Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This comparative pharmacokinetic study is being conducted to provide supporting evidence for inclusion in dossiers to regulatory authorities for an Article 8(3) of Directive 2001/83/EC abridged application for ibuprofen and pseudoephedrine liquid capsules (200 mg ibuprofen & 30 mg pseudoephedrine).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: January 30, 2017
• Est. primary completion date: January 30, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects who have given written informed consent.

2. Age: = 18 years = 50 years.

3. Body Mass Index (BMI) of = 20 and = 30 kg/m2.

4. Healthy as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.

5. Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception unless of non-childbearing potential or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject from first dose until 3 months after the final dose of study medication.

6. Female subject of non-child bearing potential with negative pregnancy test at the screening visit.

7. Male subject willing to use an effective method of contraception unless anatomically sterile or where abstaining from sexual intercourse in line with the preferred and usual lifestyle of the subject from first dose until 3 months after the final dose of study medication.

Exclusion Criteria:

1. Pregnant or lactating females.

2. A history and/or presence of significant disease of any body system, including psychiatric disorders.

3. Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.

4. A history of allergy or intolerance related to treatment with ibuprofen, aspirin, other NSAIDs, pseudoephedrine, other sympathomimetic or catecholamine derivative decongestant drugs or the excipients of the formulations.

5. A history of or active peptic or duodenal ulcers or gastro-intestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.

6. A history of hypertension or hypertension that is currently treated with antihypertensive medication.

7. A history of frequent dyspepsia, e.g. heartburn or indigestion.

8. A history of migraine.

9. Current smokers and ex-smokers who have smoked or used nicotine replacement products during the previous 6 months prior to first dosing.

10. A history of substance abuse (including alcohol).

11. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc.; total caffeine intake per day above 300 mg).

12. Those with positive screen/test for drugs of abuse and alcohol.

13. Those with a positive screen for ibuprofen.

14. Ingestion of a prescribed drug at any time in the 14 days before the first dose of study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers 30 days prior to the first dose of study medication.

15. Ingestion of an over-the-counter preparation within 7 days before the first dose of study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen, other NSAIDs or decongestants.

16. Donation of blood in quantity > 400 ml e.g. to the blood transfusion service in the 12 weeks prior to the first dose of study medication

17. Known human immune deficiency virus (HIV) positive status, or a positive viral serology screen.

18. Topical use of ibuprofen within 7 days before the first dose of study medication.

19. Those previously randomised into this study.

20. Those who are an employee at the study site.

21. Those who are a partner or first degree relative of the Investigator.

22. Those who have participated in a clinical trial in the 12 weeks prior to the first dose of study medication.

23. Those unable in the opinion of the Investigator to comply fully with the study requirements.

24. Those who have consumed grapefruit or grapefruit juice, pummelo or Seville oranges in the 7 days prior to randomisation.

25. Those who are unwilling to consume gelatine of animal origin.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules
2 x 200 mg ibuprofen & 30 mg pseudoephedrine
• Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets
2 x 200 mg ibuprofen & 30 mg pseudoephedrine
• Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules
2 x 200 mg solubilised ibuprofen

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Reckitt Benckiser Healthcare (UK) Limited	Simbec Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The occurrence of Adverse Events.		Through study completion - Screening to study follow-up (Approx 8 weeks)
Other	Change from baseline in oral temperature.	Measured in degrees Celcius	Through study completion - Screening to study follow-up (Approx 8 weeks)
Other	Change from baseline in resting heart rate.	Measured in beats per minute	Through study completion - Screening to study follow-up (Approx 8 weeks)
Other	Change from baseline in resting blood pressure.	Measured in mmHg	Through study completion - Screening to study follow-up (Approx 8 weeks)
Other	Change from baseline in haematology testing.		Through study completion - Screening to study follow-up (Approx 8 weeks)
Other	Change from baseline in biochemistry testing.		Through study completion - Screening to study follow-up (Approx 8 weeks)
Other	Change from baseline in urinary testing.		Through study completion - Screening to study follow-up (Approx 8 weeks)
Primary	Pseudoephedrine AUC0-t for Test vs. Comparator 1.	The Test and Comparator 1 will be considered similar if for pseudoephedrine, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 1 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis: 0-48hrs
Primary	Pseudoephedrine Cmax for Test vs. Comparator 1.	The Test and Comparator 2 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 2 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis: 0-48hrs
Primary	Ibuprofen AUC0-t for Test vs. Comparator 2.	The Test and Comparator 2 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 2 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis: 0-48hrs
Primary	Ibuprofen Cmax for Test vs. Comparator 2.	The Test and Comparator 2 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 2 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis: 0-48hrs
Secondary	Ibuprofen AUC0-t for Test vs. Comparator 1.	The Test and Comparator 1 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 1 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%: • Cmax for ibuprofen (in the context of the Test vs. Comparator 1 comparison)	PK Analysis: 0-48hrs
Secondary	Ibuprofen Cmax for Test vs. Comparator 1.	The Test and Comparator 1 will be considered similar if for ibuprofen, for each corresponding PK parameter, the 90% confidence interval for the Test to Comparator 1 ratio (rounded to two decimal places) of LS geometric means is fully contained within the interval 80.00 to 125.00%:	PK Analysis: 0-48hrs
Secondary	Assessment of how fast the ibuprofen from the Test product starts to be absorbed and how quickly it reaches the therapeutic level.	T8.4 - time to reach the therapeutic level (8.4 µg/ml) for ibuprofen.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	Cn - the plasma concentration of an active at each planned nominal time-point.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	AUC0-inf - Area under the plasma concentration-time curve from administration to infinity.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	administration to infinity. AUCR - ratio AUC0-t / AUC0-inf.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	Tmax -Time until Cmax is first achieved.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	Kel - elimination rate constant.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	T1/2 - plasma concentration half-life.	PK Analysis: 0-48hrs
Secondary	Pharmacokinetic parameters will be assessed as secondary endpoints.	Tlag - time between administration and the beginning of absorption of ibuprofen. This will be calculated only for the Test.	PK Analysis: 0-48hrs